相关实验视频
Updated: Sep 12, 2025

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.5K
在第二阶段临床试验中的口服免疫疗法结果:MOTIF
Shirley Y Jiang1, Shu Cao1, Kristine Martinez1
1Sean N Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, United States.
Frontiers in allergy
|August 6, 2025
概括
对过敏的口服免疫疗法 (OIT) 是安全有效的,导致大多数参与者的敏感性降低. 许多人在OIT之后实现了持续的不响应,随后避免了.
科学领域:
- 食物过敏研究 食物过敏研究
- 临床免疫学 临床免疫学
- 过敏原特异性免疫疗法
背景情况:
- 过敏是一种普遍存在的食物过敏原,与频繁的急诊所访问有关.
- 目前对过敏的治疗选择有限,需要对有效疗法的研究.
研究的目的:
- 在临床试验中评估口服免疫疗法 (OIT) 的安全性和有效性.
- 评估在 OIT.之后的脱敏和持续不响应.
主要方法:
- 第二阶段临床试验 (MOTIF,NCT03504774) 涉及12名年龄在7-55岁之间的参与者,他们对过敏.
- OIT管理了高达1,000毫克的蛋白,在52周和58周进行评估.
- 主要终点:对特定过敏原T细胞的CD28表达的变化.
主要成果:
- 对4,043毫克蛋白的脱敏化在58.3% (治疗意图) 和87.5% (每条协议) 的参与者中实现.
- 持续不响应 (SU) 在完成OIT的参与者中达到了87.5%.
- 副作用很常见 (75%),但大多是轻微的 (88%级 1);没有严重反应或使用上腺素.
结论:
- OIT是一种安全有效的治疗过敏的方法.
- 大多数参与者成功实现了脱敏,并持续不响应.
- 需要进一步研究以了解免疫学变化,因为没有观察到CD28表达的显著差异.
更多相关视频
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
8.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.4K

